Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMP-105
- Development stage
- Preclinical
- Lead developer
- Amphastar Pharmaceuticals
- Modality
- Peptides
01
Overview
AMP-105 is a first-in-class, endogenous-derived peptide being developed by Amphastar Pharmaceuticals (specifically its subsidiary Amphastar France Pharmaceuticals) for the treatment of various solid tumors and hematologic malignancies. Licensed from Nanjing Anji Biotechnology, the drug utilizes a novel mechanism of action to suppress cell growth and inhibit metastasis. Preclinical studies have demonstrated broad anti-tumor activity across several indications, including head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), lymphoma, and multiple myeloma. The product is based on an endogenous peptide discovery that potentially suppresses the growth and metastasis of multiple poorly treated cancers.
Beyond the preview
Go deeper on AMP-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMP-105.